MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s40261-023-01323-1

Медицинская библиотека · Clinical drug investigation · 2023

Key Drivers of Coagulation Factor Use in Von Willebrand Disease During Hospitalization: An Overview of the French BERHLINGO Cohort.

Horvais Valérie, Beurrier Philippe, Cussac Vincent, Pan-Petesch Brigitte, Schirr-Bonnans Solène, Rose Johann, Bayart Sophie, Ternisien Catherine, Fouassier Marc, Sigaud Marianne, Babuty Antoine, Drillaud Nicolas, Guillet Benoît, Trossaërt Marc, BERHLINGO Consortium

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Von Willebrand disease (VWD) is the most common inherited bleeding disorder. However, studies of hospitalisation patterns with replacement treatment are scarce.

OBJECTIVES

The aim of this study was to investigate the current therapeutic management of VWD and determine the key drivers of coagulation factor uses in patients during hospitalisation.

METHODS

Hopscotch-WILL was a multi-centric retrospective study conducted over a 48-month period in any patients with VWD. The data were collected from the BERHLINGO Research Database and the French Hospital database.

RESULTS

A total of 988 patients were included; 153 patients (15%) were hospitalised during 293 stays requiring treatment with von Willebrand factor (VWF) concentrates-pure or in association with Factor VIII (FVIII). Their median basal concentrations of VWF and FVIII were significantly lower than in untreated patients: VWF antigen < 30 IU/dL, VWF activity < 20 IU/dL and FVIII:C < 40 IU/dL. The median (interquartile range) concentrate consumption was similar between highly purified VWF or VWF combined with FVIII (72 [110] vs 57 [89] IU/kg/stay, p = 0.154). The use of VWF was highly heterogeneous by VWD type; type 3 had a particularly high impact on VWF consumption in non-surgical situations. The main admissions were for ear/nose/throat, hepato-gastroenterology, and trauma/orthopaedic conditions, besides gynaecological-obstetric causes in women.

CONCLUSIONS

The use of VWF concentrates is mostly influenced by low basal levels of VWF and FVIII, but also by VWD type or the cause for hospitalisation. These results could inform future studies of newly released recombinant VWF.

Для цитирования: Horvais Valérie, Beurrier Philippe, Cussac Vincent, Pan-Petesch Brigitte, Schirr-Bonnans Solène, Rose Johann, Bayart Sophie, Ternisien Catherine, Fouassier Marc, Sigaud Marianne, Babuty Antoine, Drillaud Nicolas, Guillet Benoît, Trossaërt Marc, BERHLINGO Consortium. Key Drivers of Coagulation Factor Use in Von Willebrand Disease During Hospitalization: An Overview of the French BERHLINGO Cohort.. Clinical drug investigation. 2023. DOI: 10.1007/s40261-023-01323-1.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.